#United States #Nashville #Clinical Research #InFocus Clinical #Elizabeth Nanouris

Elizabeth Nanouris Takes on Leadership Role at InFocus Clinical Research

In a significant move for its growth trajectory, InFocus Clinical Research, a unique entity specializing in global full-service retina clinical trials, has appointed Elizabeth Nanouris as the new Vice President of Business Operations. This announcement marks a pivotal enhancement of the company's operational leadership as it seeks to fortify its position in the retinal health sector.

With a career spanning over two decades, Nanouris brings a wealth of experience that encompasses essential areas like quality assurance, project management, and business development. Her unique perspective allows her to view the operational demands of clinical trials through a comprehensive lens, which is critical for organizations navigating the complexities of clinical research.

Nanouris’s expertise is not just theoretical—she has played pivotal roles in guiding organizations through substantial growth phases, ensuring they adhere to the stringent quality standards necessary for enduring success. She has significant experience supporting global Phase 3 program launches and building robust proposal frameworks. Furthermore, her ability to cultivate and advance partnerships is key to translating early-stage scientific innovations into actionable clinical developments.

Brad Doerschuk, CEO of InFocus Clinical Research, expressed strong confidence in Nanouris's capabilities by stating, “The best clinical organizations aren't built on headcount; they're built on people who understand both the business and the science.” His recognition of her experience aligns with the growing demands of the company’s expanding global retina clinical trial portfolio.

In her new role, Nanouris is tasked with crucial responsibilities, including solidifying existing sponsor partnerships, refining proposal development and contract processes, and steering the company toward operational excellence aligned with their retina-focused clinical partners. She articulated her enthusiasm for joining InFocus, emphasizing the importance of aligning strategy with execution, which she believes is essential for delivering impactful results in the competitive landscape of retina disease research. “The retina space requires a unique combination of clinical expertise and operational precision,” Nanouris elaborated. “What drew me to InFocus is its clear commitment to doing one thing exceptionally well. That alignment between strategy and execution is rare and supports strong results for sponsors targeting retina diseases.”

About InFocus Clinical Research
Founded in 2014, InFocus Clinical Research has emerged as the only global, full-service clinical research organization dedicated exclusively to retina studies. With offices strategically located in Australia, China, Europe, Latin America, and the United States, InFocus is paramount for pharmaceutical and biotech companies that are advancing innovative therapies for retinal diseases. The organization is currently involved in clinical trials across at least 18 countries worldwide, demonstrating its significant reach and influence in the clinical research community. To learn more about their impactful work, visit infocusclinical.com.

As InFocus embarks on this new chapter in its journey, the appointment of Elizabeth Nanouris underscores its commitment to excellence in retinal clinical research, promising exciting developments in the field ahead.